Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: Is there hope?

World Journal of Gastroenterology

Volumn 17, Issue 38, 2011, Pages 4251-4257

  Salari, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benzodiazepine receptor modulators; Benzodiazepines; Dextofisopam; Irritable bowel syndrome; Systematic review

Indexed keywords

ALOSETRON; ASIMADOLINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CIMETROPIUM; CLONIDINE; CYTOKINE; DESIPRAMINE; DEXLOXIGLUMIDE; EZLOPITANT; GABAPENTIN; LINACLOTIDE; LOXIGLUMIDE; MELATONIN; NALOXONE; NALTREXONE; NEPADUTANT; NEUROTROPHIN 3; PAROXETINE; PREGABALIN; RENZAPRIDE; SCOPOLAMINE; SOLABEGRON; SOLIFENACIN; TEGASEROD; TOFISOPAM; VENLAFAXINE; ZAMIFENACIN;

CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; IRRITABLE COLON; MEDICAL LITERATURE; MENTAL DISEASE; NEUROIMMUNOLOGY; PATHOGENESIS; PSYCHOTHERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN;

EID: 80955151296     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i38.4251     Document Type: Editorial

References (95)

1. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology,natural history,health care seeking andemerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204
2. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghulahusk. Br Med J 1979; 1: 376-378
3. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122: 2032-2048
4. Schwetz I, Bradesi S, Mayer EA. Current insights into the pathophysiology of irritable bowel syndrome. Curr Gastroenterol Rep 2003; 5: 331-336
5. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D,BaxterK,Ryks M,ZinsmeisterAR. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-781
6. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-293
7. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-261
8. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122: 2078-2080
9. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-153
10. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406
11. Jones MP, Dilley JB, Drossman D, Crowell MD. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103
12. Shanahan F. Brain-gut axis and mucosal immunity: a perspective on mucosal psychoneuroimmunology. Semin Gastrointest Dis 1999; 10: 8-13
13. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010; 6:1:49-55
14. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacyof probiotics in irritable bowel syndrome: ameta-analysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780
15. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable andinflammatorybowel diseases: role of ATP. Recent Pat Endocr Metab Immune Drug Discov 2009; 3:69-75
16. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-553
17. Rahimi R, Nikfar S, Abdollahi M. Efficacyandtolerabilityof alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled,12-week trials. Clin Ther 2008; 30: 884-901
18. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacyof tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15: 1548-1553
19. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors forthe management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci 2008; 4:71-76
20. Talley NJ. Newer antidepressants in irritable bowel syndrome: what is the evidence? Arch Med Sci 2008; 4:77-78
21. Ghaith O, El-Halabi M, Hashash JG, Sharara AI. Investigational agents for the irritable bowel syndrome. Expert Opin Investig Drugs 2010; 19: 1161-1178
22. Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr Pharm Des 2010; 16: 3646-3655
23. Zamani MJ, Sharifzadeh M, Rezaie A, Mashayekhi F, Abdollahi M. Effects of sildenafil on rat irritable bowel syndrome. Therapy 2005; 2:237-242
24. Bulmer DCE, Coelho AM, Winchester WJ. Approaches to the treatment of visceral pain. Drug Discovery Today: Therapeutic Strategies 2007; 4:171-176
25. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Alteredrectal perception is abiological markerof patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
26. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002; 51 Suppl 1: i67-i71
27. Naliboff BD, Derbyshire SW, Munakata J, Berman S, Mandelkern M, Chang L, Mayer EA. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001; 63: 365-375
28. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118: 842-848
29. Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, Fournet J, Segebarth C. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 2002; 97: 654-661
30. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409
31. Spiller RC. Role of nerves in enteric infection. Gut 2002; 51: 759-762
32. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role forinflammation in irritable bowel syndrome? Gut 2002; 51 Suppl 1: i41-i44
33. Mayer EA, Naliboff BD, Chang L, Coutinho SV. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2001; 280: G519-G524
34. Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut 2002; 51 Suppl 1: i29-i33
35. Mozaffari S, Esmaily H, Rahimi R, Baeeri M, Sanei Y, Asadi-Shahmirzadi A, Salehi-Surmaghi MH, Abdollahi M. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn Mag 2011; 7:213-223
36. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004; 558: 263-275
37. Greenwood-Meerveld B, Barron KW. Tonic GABA (A) receptor-mediated neurotransmission in the dorsal vagal complex regulates intestinal motility in rats. Eur J Pharmacol 1998; 346: 197-202
38. Gentilini G, Franchi-Micheli S, Pantalone D, Cortesini C, Zilletti L. GABAB receptor-mediated mechanisms in human intestine in vitro. Eur J Pharmacol 1992; 217: 9-14
39. Grundmann O, Yoon SL, Moshiree B. Current developments for the diagnosis and treatment of irritable bowel syndrome. Curr Pharm Des 2010; 16: 3638-3645
40. Castedal M, Björnsson E, Abrahamsson H. Effects of midazolam on small bowel motility in humans. Aliment Pharmacol Ther 2000; 14: 571-577
41. Yamaguchi K, Suzuki K, Niho T, Shimora M, Ito C, Ohnishi H. Tofisopam,anew 2,3-benzodiazepine. Inhibition of changes induced by stress loading and hypothalamic stimulation. Can J Physiol Pharmacol 1983; 61: 619-625
42. Iovino P, Azpiroz F, Domingo E, Malagelada JR. The sympathetic nervous system modulates perception and reflex responses to gut distention in humans. Gastroenterology 1995; 108: 680-686
43. Horváth EJ, Horváth K, Hámori T, Fekete MI, Sólyom S, Palkovits M. Anxiolytic 2,3-benzodiazepines,theirspecific binding to the basal ganglia. Prog Neurobiol 2000; 60: 309-342
44. Leventer SM, Kucharik RF, Keogh JC, Karen R, Kimm BG, Naidong Y, Brian TS, Judi G, Jess A, Kevin LK. The potential of dextofisopam fortreatment of irritable bowel syndrome andinflammatorybowel disease. Am J Gastroenterol 2004; 99:S279
45. Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 197-206
46. Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol Motil 2008; 20: 1086-1093
47. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95-99
48. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000; 85: 405-414
49. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215-224
50. Lu Y, Westlund KN. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 1999; 290: 214-219
51. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 981-988
52. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2-deltatype 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modifiedmice. Brain Res 2006; 1075: 68-80
53. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82
54. Million M, Wang L, Adelson DW, Roman F, Diop L, Taché Y. Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats. Gut 2007; 56: 1482-1484
55. Diop L, Raymond F, Fargeau H, Petoux F, Chovet M, Doherty AM. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002; 302: 1013-1022
56. Ravnefjord A, Brusberg M, Larsson H, Lindström E, Martínez V. Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br J Pharmacol 2008; 155: 407-416
57. Brusberg M, Ravnefjord A, Martinsson R, Larsson H, Martinez V, Lindström E. The GABA(B) receptoragonist,baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral pain-related responses to colorectal distension in rats. Neuropharmacology 2009; 56: 362-367
58. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56: 1218-1225
59. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783
60. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increasedrectal mucosal enteroendocrine cells,Tlymphocytes,andincreasedgut permeabilityfollowing acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811
61. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsyof the jejunum reveals inflammation andenteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979
62. Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001; 120: 1729-1736
63. De Giorgio R, Barbara G, Blennerhassett P, Wang L, Stanghellini V, Corinaldesi R, Collins SM, Tougas G. Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in the nematode infected rat. Gut 2001; 49: 822-827
64. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months afterbacterial gastroenteritis andrisk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-782
65. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702
66. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses andrelationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
67. Aerssens J, Camilleri M, Talloen W, Thielemans L, Göhlmann HW, Van Den Wyngaert I, Thielemans T, De Hoogt R, Andrews CN, Bharucha AE, Carlson PJ, Busciglio I, Burton DD, Smyrk T, Urrutia R, Coulie B. Alterations in mucosal immunityidentifiedin the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205
68. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to toll-like receptors andbeyond- current knowledge andfuture research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 363-373
69. O'Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Crya rya rya n JF, Dinan TG. Earlylife stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 2009; 65: 263-267
70. Kalashnikov SV, Kalashnikova EA, Kokarovtseva SN. Immunomodulating effects of tofizopam (Grandaxin) anddiazepam in vitro. Mediators Inflamm 2002; 11: 53-59
71. Savino W, Dardenne M. Immune-neuroendocrine interactions. Immunol Today 1995; 16: 318-322
72. Olsen RW, Tobin AJ. Molecularbiologyof GABAA receptors. FASEB J 1990; 4: 1469-1480
73. Zisterer DM, Williams DC. Peripheral-type benzodiazepine receptors. Gen Pharmacol 1997; 29: 305-314
74. Drugan RC. Are the nonmitochondrial peripheral benzodiazepine receptors on leukocytes anovel intermediaryof brain, behavior, and immunity? Lab Invest 1994; 70: 1-5
75. Zavala F, Haumont J, Lenfant M. Interaction of benzodiazepines with mouse macrophages. Eur J Pharmacol 1984; 106: 561-566
76. Zavala F, Masson A, Brys L, de Baetselier P, Descamps-Latscha B. A monoclonal antibody against peripheral benzodiazepine receptor activities the human neutrophil NADPH-oxidase. Biochem Biophys Res Commun 1991; 176: 1577-1583
77. Cahard D, Canat X, Carayon P, Roque C, Casellas P, Le Fur G. Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest 1994; 70: 23-28
78. Ferrarese C, Appollonio I, Bianchi G, Frigo M, Marzorati C, Pecora N, Perego M, Pierpaoli C, Frattola L. Benzodiazepine receptors anddiazepam binding inhibitor: A possible link between stress, anxiety and the immune system. Psycho-neuroendocrinology 1993; 18: 3-22
79. Ikezaki K, Black KL. Stimulation of cell growth andDNA synthesis by peripheral benzodiazepine. Cancer Lett 1990; 49: 115-120
80. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA 1977; 74: 3805-3809
81. Petócz L. Pharmacologic effects of tofizopam (Grandaxin). Acta Pharm Hung 1993; 63: 79-82
82. Walker EA, Roy-Byrne PP, Katon WJ. Irritable bowel syndrome and psychiatric illness. Am J Psychiatry 1990; 147: 565-572
83. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacyof antidepressants andpsychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378
84. Stockbrügger R, Coremans G, Creed F, Dapoigny M, Müller-Lissner SA, Pace F, Smout A, Whorwell PJ. Psychosocial backgroundandintervention in the irritable bowel syndrome. Digestion 1999; 60: 175-186
85. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Schuster MM. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95: 709-714
86. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasmacytokines as apotential biomarker? Gastroenterology 2006; 130: 304-311
87. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking forirritable bowel syndrome andnonulcerdyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001; 96: 1340-1349
88. Dinan TG. Stress: the shared common component in major mental illnesses. Eur Psychiatry 2005; 20 Suppl 3: S326-S328
89. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, Read N, Silk D, Whorwell P. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000; 47 Suppl 2: ii1-ii19
90. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131
91. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004; 72: 1100-1113
92. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72
93. Käll E, Lindström E, Martinez V. The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur J Pharmacol 2007; 570: 203-211
94. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitorcitalopram in irritable bowel syndrome. Gut 2006; 55: 1095-1103
95. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: afive-yearclinical experience. Aliment Pharmacol Ther 1994; 8: 409-416